Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults

Diabetic Medicine

Volumn 22, Issue 9, 2005, Pages 1141-1145

  Jimba, S ^a,b   Nakagami, T ^b   Takahashi, M ^a   Wakamatsu, T ^a   Hirota, Y ^a   Iwamoto, Y ^b   Wasada, Taro ^a,b  

^a Saitama ken Saiseikai Kurihashi Hospital   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Impaired fasting glucose; Non alcoholic fatty liver disease; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN; TRIACYLGLYCEROL;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PERIODIC MEDICAL EXAMINATION; PREVALENCE; QUESTIONNAIRE; REGRESSION ANALYSIS; STATISTICAL MODEL;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; FATTY LIVER; FEMALE; GLUCOSE; GLUCOSE METABOLISM DISORDERS; HUMANS; JAPAN; LIVER; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; SEX DISTRIBUTION;

EID: 24044467100     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01582.x     Document Type: Article

References (25)

1. Spiro HM. Primary structural disorders. In: Spriro, HM, ed. Clinical Gastroenterology. New York: McGraw-Hill 1993, 1059-1108.
2. Aramaki T, Oosuga M. NASH and fatty liver. Shindan Chiryou 2001; 89: 1839-1844 (in Japanese).
3. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110.
4. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986; 220: 83-88.
5. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
6. Clark JM, Diehl AM, Brancati FL. Nonalcoholic fatty liver disease and the risk of type 2 diabetes in the United States. Diabetes 2001; 50: A38.
7. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455.
8. Seppala-Lindroos A, Vehkavaara S, Hakkinen A-M, Goto T, Westerbacka J, Sovijarvi A et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028.
9. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
10. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11: 560-565.
11. World Health Organization. Report of a WHO consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organisation 1999: WHO/NCD/NCS/99.2.
12. Matsumoto K, Miyake S, Yano M, Ueki Y, Yamaguchi Y, Akazawa S et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 1997; 20: 1562-1568.
13. Gore RM. Diffuse liver disease. In: Gore, RM, Levine, MS, Laufer, I, eds. Textbook of Gastrointestinal Radiology. Philadelphia: Saunders 1994: 1968-2017.
14. Japanese Society of Hypertension. Japanese Society of Hypertension Guideline for the Management of Hypertension (JSH 2000). Tokyo, Japan: Japanese Society of Hypertension 2000 (in Japanese).
15. Japan Atherosclerosis Society. Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Atherosclerotic Cardiovascular Disease. Tokyo, Japan: Japan Atherosclerosis Society 2000 (in Japanese).
16. Japanese Society of Gout and Nucleic Acid Metabolism. Guideline for the Management of Hyperuricemia and Gout. Tokyo, Japan: Japanese Society of Gout and Nucleic Acid Metabolism 2002 (in Japanese).
17. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142-149.
18. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117.
19. Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 2004; 28: 167-172.
20. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986; 292: 13-15.
21. Nomura F, Ohnishi K, Satomura Y, Ohtsuki T, Fukunaga K, Honda M et al. Liver function in moderate obesity-study in 534 moderately obese subjects among 4613 male company employees. Int J Obes 1986; 10: 349-354.
22. Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991; 43: 26-31.
23. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.
24. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum γ-glutamyltransferase and risk of NIDDM. Diabetes Care 1998; 21: 732-737.
25. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: 3010-3014.